Immunext

ImmuNext is developing immune-based therapeutics to treat patients with immune-related disorders, including autoimmunity, cancer, transplantation rejection, and infectious disease. We are targeting critical immunomodulatory molecules that either promote or suppress immune responses to restore immune homeostasis and cure disease. Using antibody-based therapeutics, a spectrum of newly identified molecules are being targeted to achieve disease remission. Our core competencies are discovery, target biology and pre-clinical drug development. ImmuNext assets:* Immunometabolic Checkpoint Target.Partnered with Eli Lilly in March 2019, therapies targeting a novel transporter target are shown to regulate immune cell metabolism. This opens novel opportunity for treatment of indications with currently limited therapeutic avenues.* Anti-VISTA, a negative checkpoint regulator antagonist for the treatment of cancer, is in the clinic. Partnered with Johnson and Johnson subsidiary, Janssen Biotech, in September, 2012.* VISTA agonists for the treatment of autoimmune disease. Partnered with Hoffman-La Roche in December, 2016, ImmuNext is developing antibodies to VISTA to suppress immune response in multiple inflammatory diseases. The impact of these antibodies is due to the direct suppression of immune cells leading to immune suppression and long term tolerance.* Anti-CD40L antagonists, re-engineered for safety and efficacy. Anti-CD40L was partnered with Sanofi in January, 2017. CD40L (CD154) is a highly validated, superlative therapeutic target in autoimmunity and graft rejection. Dr. Noelle, who discovered CD40L, has re-engineered antagonist antibodies to avoid thromboembolic concerns while maintaining efficacy.*Other programs include a CD40 agonist More: Portfolio - http://immunext.com/portfolio/ Careers - http://immunext.com/careers/